In October 2017, the US Food and Drug Administration approved the recombinant shingles vaccine (marketed as Shingrix) as a replacement for the live-virus vaccine because it was more effective at protecting people aged 50 years or older against herpes zoster, or shingles. Now an observational study in Nature Medicine suggests it may offer better protection against dementia too.
